Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Abstract

This study reports 2-year survival outcomes among patients with advanced nonprogressive stage IIA to IV lung cancer randomized to symptom monitoring during chemotherapy via web-based patient-reported outcomes vs standard scheduled imaging after treatment to detect symptomatic recurrence.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported.

Figures

Figure 1.. Assignment, Follow-up, and Analysis of the Study Patients

At 9 months when recruitment was halted, 10 patients in the intervention group and 27 patients in the control group had died. Of the 34 living patients in the control group, 10 had not relapsed and crossed over to the intervention.

Figure 2.. Kaplan-Meier Curves for the Overall Survival (OS) Analysis

A total of 121 patients were included in the intention-to-treat survival analysis. Ten of 34 living patients in the control group were eligible to cross over following the interim analysis. HR indicates hazard ratio.